Clinuvel Pharmaceuticals (FRA:UR9) 3-Year Book Growth Rate : 30.70% (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals 3-Year Book Growth Rate?

Clinuvel Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was €2.19.

During the past 12 months, Clinuvel Pharmaceuticals's average Book Value per Share Growth Rate was 26.50% per year. During the past 3 years, the average Book Value per Share Growth Rate was 30.70% per year. During the past 5 years, the average Book Value per Share Growth Rate was 31.60% per year. During the past 10 years, the average Book Value per Share Growth Rate was 29.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Clinuvel Pharmaceuticals was 48.60% per year. The lowest was -31.90% per year. And the median was 1.50% per year.

Competitive Comparison of Clinuvel Pharmaceuticals's 3-Year Book Growth Rate

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's 3-Year Book Growth Rate falls into.

Clinuvel Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Clinuvel Pharmaceuticals (FRA:UR9) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Clinuvel Pharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (FRA:UR9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (FRA:UR9) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

CLVLY:USA CLVLF:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (FRA:UR9) Headlines

No Headlines